Deferred Tax Calculator
for Healthcare

IAS 12 deferred tax for Healthcare

Healthcare entities span a wide range from private hospital groups to pharmaceutical manufacturers to medical device companies, and each generates distinct temporary differences under IAS 12. A private hospital group with EUR 80M in diagnostic and surgical equipment will have significant taxable temporary differences where tax depreciation exceeds accounting depreciation. A pharmaceutical company with EUR 150M in capitalised Phase III development costs holds a deferred tax liability if the jurisdiction allowed immediate tax deduction of the research spend. Medical device companies selling products with long warranty periods carry deductible temporary differences on warranty provisions. The common thread is that healthcare entities carry large specialised asset bases and operate under strict regulatory requirements that create provisions.

The technical IAS 12 considerations for healthcare depend on the sub-sector. For pharmaceutical companies, the main deferred tax driver is development costs capitalised under IAS 38.57 where the jurisdiction permits immediate tax deduction. This creates a pattern similar to technology companies: the carrying amount is the capitalised cost less amortisation, the tax base is zero, and a deferred tax liability arises. However, pharmaceutical development has a unique twist: if a drug fails clinical trials, the capitalised asset is impaired or written off, and the temporary difference reverses immediately. The deferred tax liability is released to profit or loss in the same period. For hospital groups, the deferred tax profile looks more like manufacturing: heavy fixed assets, lease portfolios for medical equipment, and provisions for medical malpractice or clinical negligence claims. These provisions create deductible temporary differences where the tax deduction follows payment of the claim, which may be years after the provision is recognised. For medical device companies, warranty provisions and post-market surveillance obligations under MDR (EU Medical Device Regulation 2017/745) create provisions with no immediate tax deduction.

Audit findings in healthcare deferred tax centre on the recoverability of deferred tax assets on R&D-related losses, the identification of all temporary differences in complex group structures, and transfer pricing in pharmaceutical groups. Pharmaceutical companies in growth phases often accumulate tax losses while spending heavily on clinical trials. IAS 12.35 requires convincing evidence of future taxable profits for entities with a history of losses, and regulators have found that auditors accept pipeline revenue forecasts without testing the probability of regulatory approval (which for Phase II drugs averages around 30% historically). In hospital groups, audit inspections have identified failures to recognise deferred tax on provisions for clinical negligence claims, particularly where the claims are long-tail and the provision is re-estimated annually. A third area is transfer pricing in pharmaceutical groups: intercompany royalties and cost-sharing arrangements for drug development create complex temporary difference patterns that require careful mapping of carrying amounts and tax bases across multiple jurisdictions.

Set up the calculator by identifying the main balance sheet categories for your healthcare entity. For pharmaceutical companies: capitalised development costs, in-process R&D acquired in business combinations, inventory (including work-in-progress for drugs in clinical trials), and provisions for product liability or returns. For hospital groups: medical equipment, right-of-use assets for leased equipment, provisions for clinical negligence, and defined benefit pension obligations. For medical device companies: capitalised development costs, warranty provisions, and inventory. Enter carrying amounts from the IFRS balance sheet and tax bases from the tax computation for each item.